Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference By: AlloVir, Inc. via Business Wire September 07, 2021 at 07:00 AM EDT AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate update at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14th at 4:15 p.m. ET. The presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation. About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single, and multi-virus-specific T-cells targeting devastating viruses for patients with T-cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com or follow us on Twitter or LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005080/en/Contacts Media: Courtney Heath ScientPR AlloVirPR@scientpr.com 617-872-2462 Investor: Medha Chadha AlloVir ir@allovir.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference By: AlloVir, Inc. via Business Wire September 07, 2021 at 07:00 AM EDT AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate update at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14th at 4:15 p.m. ET. The presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation. About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single, and multi-virus-specific T-cells targeting devastating viruses for patients with T-cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com or follow us on Twitter or LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005080/en/Contacts Media: Courtney Heath ScientPR AlloVirPR@scientpr.com 617-872-2462 Investor: Medha Chadha AlloVir ir@allovir.com
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate update at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14th at 4:15 p.m. ET. The presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation. About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single, and multi-virus-specific T-cells targeting devastating viruses for patients with T-cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com or follow us on Twitter or LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005080/en/
Media: Courtney Heath ScientPR AlloVirPR@scientpr.com 617-872-2462 Investor: Medha Chadha AlloVir ir@allovir.com